4:15 PM ET
8-K
Business Update
MoonLake Immunotherapeutics Business Update
MoonLake Immunotherapeutics has submitted a Biologics License Application (BLA) to the FDA for its tri-specific nanobody sonelokimab. The application seeks approval for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients. The company expects notification regarding the acceptance of the BLA for review within approximately 60 days.
- Counterparty
- FDA